The FDA determined that another recall of BD (NYSE:BDX) Alaris infusion pumps is Class I, the most serious kind. In the latest Alaris recall, the company cites compatibility issues with Cardinal Health Monoject syringes. The issue mainly relates to changes made to the products by Cardinal Health. It affects more than 1 million total devices. […]
Cardinal Health
FDA issues warning about over-the-counter eye drops
The FDA issued a notice warning consumers about 26 over-the-counter eye drop products that could result in eye infections. In its notice, the FDA instructed consumers not to purchase and to immediately stop using these products. Using those eye drops could lead to the risk of infections that could result in partial vision loss or […]
Cardinal Health recalls some saline syringes due to air embolism risk
Cardinal Health (NYSE:CAH) has initiated a U.S. recall of its Monoject Flush prefilled saline syringes due to an issue with the reintroduction of air. Dublin, Ohio-based Cardinal Health on Aug. 4 recalled approximately 267 million Monoject Flush devices because they have been found to reintroduce air into the syringe after the air has been expelled, […]
Cardinal Health wins new FDA approval for Lymphoseek
Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use. Dublin, Ohio-based Cardinal Health touts Lymphoseek — acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016 — as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies (SLNB). The new indication will expand […]
Report: Global syringes market set to reach $32.4B by 2027
Market research released this week suggests that the global syringes market will reach $32.39 billion by 2027. Allied Market Research published a report estimating the global syringes market sat at $15.34 billion in 2019, with expectations of hitting $32.39 billion in value by 2027, with a compound annual growth rate (CAGR) of 9.6% from 2020 […]
Medinol stent performs just as well as Medtronic Resolute, study says
The EluNIR drug-eluting stent made by Medinol performed just as well as the Resolute Integrity or Resolute Onyx stents from Medtronic (NYSE:MDT), according to new clinical study results from an international team of researchers. The randomized clinical trial — conducted by researchers from the U.S., Israel, Canada and the Netherlands — involved 2,221 people and compared […]
Sollis lands $50m for extended-release pain-relief drug
Sollis Therapeutics closed a $50 million round to support a pivotal trial of its non-opioid pain-reliever, according to Ohio-based translator NeuroTechnology Innovations Translator. Deerfield Management led the funding round and was joined by NIT collaborators, including Medtronic (NYSE:MDT), Cardinal Health and Ohio State University. NIT founded Sollis Therapeutics last year to help facilitate the development and commercialization […]
Cardinal Health donates 80,000 Narcan doses to first responders in Appalachia
Cardinal Health today began its donation of more than 80,000 doses of Narcan, a nasal spray designed to reverse opioid overdoses, to community organizations in Ohio, Kentucky, Tennessee and West Virginia. The donation is part of the company’s Opioid Action Program – a pilot program launched last year to bring solutions to first responders, communities […]
Cordis, Medinol tout first commercial implants of Elunir drug-eluting stent in U.S.
Cordis and Medinol announced today that the first commercial uses of the Elunir drug-eluting stent in the U.S. were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute in Atlanta. The Elunir stent, developed by Medinol and distributed by Cordis, features a metallic spring tip and the narrowest strut width of […]
Medtech stories we missed: Feb. 3, 2017
From disappointing Getinge earnings to a $2.25 billion U.S. Defense Department contract for Cardinal Health to a host of 510(k) clearances, here are seven recent medtech stories that are still worth a mention. 1. Getinge disappoints on earnings—again Getinge stock took a nearly 10% tumble last week after releasing earnings that Reuters says lagged analyst […]
